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ABSTR ACT: Soluble cancer-related protein biomarker levels may be increased in subjects without findings at large bowel endoscopy performed due 
to symptoms associated with colorectal cancer. The present study focused on a possible association between increased biomarker levels in such subjects 
and subsequent development of malignant diseases. In a major study of 4,990 subjects undergoing large bowel endoscopy, 691 were without pathology 
and comorbidity. Plasma levels of TIMP-1, CEA, CA19-9, and YKL-40 were determined in samples collected just before endoscopy and compared 
with subsequent development of a malignant disease within a period of 7–8 years. The upper 90% limits of the reference levels of every single protein 
were used to differentiate between normal and increased levels. The levels were separated into three groups: 0, none of the biomarkers increased; 1, 
one  biomarker increased; 2, two or more biomarkers increased. A total of 43 subjects developed a primary malignant disease in the observation period. 
Univariatly, increase of all four biomarkers was significantly associated with subsequent development of a malignant disease. A multivariate analysis 
showed that increased biomarker levels were associated with subsequent development of a malignant disease (P = 0.002). The cumulative risk of develop-
ing malignant disease within the first 5 years after endoscopy was group 0, 3.3%; group 1, 5.8%; group 2, 7.8%. It is concluded that increased levels of 
plasma TIMP-1, CEA, CA19-9, and serum YKL-40 at large bowel endoscopy without findings may be associated with an increased risk of developing 
a subsequent malignant disease.
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Introduction
Screening leads to improved survival among patients with 
colorectal cancer (CRC).1–3 The statement is supported by 
the results of population screening for CRC showing more 
individuals being diagnosed with early-stage disease,4,5 which 
translates into improved survival compared to CRC patients 
not diagnosed by screening.6,7 In addition, screening may lead 
to reduction of CRC incidence6 due to detection of patients 
with high-risk adenomas. Such patients are enrolled in pro-
grams with frequent follow-up colonoscopies, which reduce 
the number of patients, who develop CRC.8
The compliance of screening procedures is far from 
sufficient, with ranges of 40%–60%. This leads to clinical 
sensitivities in ranges of 30%–45%,3 meaning that 50% of 
those who may have a neoplastic large bowel lesion are not 
detected. Therefore, current research focuses on developing 
screening concepts that are accurate and acceptable by the 
screening population. Such concepts include blood-based 
 procedures,3,9,10 and compliance rates 90% for blood test-
ing have been observed among subjects referred to large bowel 
endoscopy due to symptoms of CRC.11 This supports recent 
results indicating that screenees may prefer blood-based com-
pared with feces-based screening concepts.12
Various challenges remain to be solved in the develop-
ment of blood-based biomarkers for cancer screening. Hitherto, 
most results are based on plasma or serum proteins that also 
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identify subjects with various benign diseases.3,13 Such results 
are classified as false positives and contribute to lowering the 
specificity of the tests. However, increased levels of cancer-
related protein biomarkers are identified even among healthy 
subjects of the general population, and it has been argued that 
this phenomenon may identify subjects with increased risk of 
developing a malignant disease over the following years.14 In a 
population-based study performed in 2004–2005, blood sam-
ples were collected before large bowel endoscopy of subjects 
referred due to symptoms of CRC or adherence to a hereditary 
nonpolyposis colorectal cancer (HNPCC) surveillance pro-
gram.11 Subsequently, the protein biomarkers plasma TIMP-1, 
CEA, CA19-9, and serum YKL-40 were determined.11,13–16 
Some subjects without any malignant or benign large bowel 
findings had increased levels of some or all of the four pro-
tein biomarkers. Therefore, the aim of the present study was 
to evaluate a possible association between increased biomarker 
levels in subjects, without findings at large bowel endoscopy 
and subsequent development of malignant diseases.
Methods
This present study is based on a prospective, population-based 
study performed in 2004–2005, which included 4,509 subjects 
with various symptoms of CRC and 481 subjects adhering to 
a HNPCC surveillance program. The inclusion and exclu-
sion criteria of the subjects have been presented previously.11 
Comorbidities were recorded for all subjects. Symptoms or 
adherence to HNPCC surveillance programs guided whether 
a subject was offered sigmoidoscopy or colonoscopy. Subjects 
without findings of colorectal pathology at sigmoidoscopy, 
but with persisting symptoms, were offered subsequent colo-
noscopy. Finally, subjects with persisting symptoms, without 
findings at sigmoidoscopy plus colonoscopy or colonoscopy 
alone, were offered additional examinations including ultra-
sound (US), computerized axial tomography scan (CAT), or 
magnetic resonance imaging (MRI).
The study was approved by the Regional Ethics Commit-
tee of Copenhagen and Frederiksberg no. H-KF-01-080/03 and 
The Danish Data Protection Agency no. 2003-41-3312, and 
the requirements of the Helsinki II declaration were  fulfilled. 
Subjects gave their written, informed consent to participate in 
the research. Blood samples for serum, plasma, and buffy coats 
were collected from all subjects just before endoscopy and were 
handled and subsequently frozen at −80°C under electronic 
24/7 surveillance, according to a validated standard operative 
procedure. The study was finalized on 31 December, 2005, and 
the audits were performed on-site and electronically via exist-
ing databases. TIMP-1, CEA, and CA19-9 were determined 
in ethylenediaminetetraacetic acid (EDTA) plasma using the 
Abbott ARCHITECT® i2000 automated immunoassay 
system.11 Serum YKL-40 levels were determined by a commer-
cial enzyme-linked immunosorbent assay (ELISA) platform, 
with a detection limit 10 ng/mL and intra-assay coefficient of 
variation (CV) of 5% and inter-assay CV of 6%.14
In total, 1,176 subjects had no pathology at the endos-
copy, but 388 of these subjects had self-reported comorbid-
ity or had concurrent diseases and/or were taking prescribed 
medication. Therefore, only 788 subjects were categorized as 
having no findings plus no comorbidity. However, the sub-
sequent audit disclosed that 96 subjects were registered with 
previous or concurrent malignancy or a variety of diseases 
known to be associated with increased plasma biomarker 
levels.11 Therefore, the final cohort of the present study only 
comprised 691 subjects, including 174 from the HNPCC sur-
veillance programs. Using 31 December, 2012 as the cut-point, 
the subjects were identified in the databases, and the develop-
ment of any malignant disease (except for basocellular and/
or planocellular skin cancer) during the observation period of 
7–8  years was recorded using the ICD10 codes. Some sub-
jects had developed more than one malignant disease, but only 
the very first diagnosed disease was included in the study. In 
addition, we recorded the elapsed time (ET) within which a 
subject developed the malignant disease.
Statistics
Descriptive statistics were presented by the median, minimum, 
maximum, and quartiles for continuous data. The Spearman 
rank correlation was used as a measure of association, and tests 
for comparing marker levels between strata were done using 
the Wilcoxon rank sum test. Comparisons between strata 
with adjustment for age and gender were performed using a 
linear model with the biomarker levels log transformed. The 
latter results were presented by the relative differences (ratio) 
with 95% confidence intervals (CI).
The ET to development of a malignant disease and the 
association to the biomarker levels at the endoscopy were 
analyzed with death as a competing risk.17 Each biomarker 
level has been defined as normal or elevated based on the 
90th percentile of age and gender-adjusted reference intervals. 
The reference intervals for each biomarker were constructed 
by regressing the log of each biomarker on age and gender 
using a cohort of 400 subjects referred to colonoscopy who 
were without any findings, without comorbidity, and without 
medication. Univariate analyses of time to diagnosis of pri-
mary cancer have been done for each biomarker in addition 
to the association for subjects with no elevated (group 0), one 
elevated (group 1), or two or more (group 2) elevated biomark-
ers. All subsequent primary cancers recorded in the observa-
tion period were included, but the cumulative incidence rate 
was calculated within 5 years. P-values less than 5% were con-
sidered significant.
Results
The study cohort included 376 females and 316 males, and 
the median age at endoscopy was 47 (21–91) years for women 
and 45 (21–92) for men. In total, 43 of the 691 subjects devel-
oped a malignant disease within the observation period. The 
mean ET from endoscopy to diagnosis was 39 (1–99) months. 
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A total of six subjects had primary nonbowel cancer  diagnosed 
within 6  months after endoscopy. The median age of the 
43 subjects at the time of diagnosis of their primary cancer was 
56 (26–84) years. The distribution of the diseases is shown in 
Table 1. The five subjects, who subsequently developed colon 
cancer, had right-sided lesions. Two of the five subjects had 
only been offered sigmoidoscopy at the primary examination, 
and the diagnoses of colon cancer were verified 37 months and 
84 months after the primary sigmoidoscopy, respectively.
The plasma and serum analyses showed that only 6%–11% 
of the subjects had elevated levels of the four biomarkers (Table 
2). Univariate analyses of plasma TIMP-1 and cancer devel-
opment demonstrated a significant difference between sub-
jects with normal and elevated levels: P  =  0.039 cumulative 
incidence at 5  years; normal TIMP-1 levels 4.0% (95% CI: 
2.6%–5.7%) and elevated levels 6.2% (95% CI: 2.0%–13.8%). 
Similar analysis for plasma CEA: P  =  0.028; normal CEA 
levels 3.9% (95% CI: 2.6%–5.6%) and elevated levels 6.8% 
(95% CI: 2.5%–14.0%); plasma CA19-9: P  =  0.028; normal 
CA19-9 levels 3.4% (95% CI: 2.2%–5.1%) and elevated levels 
10.5% (95% CI: 4.9%–18.7%), serum YKL-40: P = 0.043; nor-
mal YKL-40 levels 2.2% (95% CI: 0.2%–10.5%) and elevated 
levels 4.3% (95% CI: 2.9%–6.1%), respectively. A subsequent 
multivariate analysis (including all four biomarkers) showed that 
increased biomarker levels were significantly associated with 
the development of a primary malignant disease (P = 0.002).
Categorizing the subjects with no elevated biomarker 
levels (group 0), 1 elevated level (group 1), or 2 or more 
elevated levels (group 2) showed that the cumulative risk of 
developing a primary malignant disease within 5 years after 
endoscopy was: group 0: 3.3% (2.0%–5.2%); group 1: 5.8% 
(2.9%–10.3%); group 2: 7.8% (2.5%–17.3%) (Fig. 1). Pairwise 
comparisons demonstrated a significant difference between 
those with no elevated markers and with one or two elevated 
markers, P = 0.024 and P = 0.0009, respectively. However, the 
difference between those with one or two elevated markers 
was not significant, P = 0.20.
Six patients had a nonbowel malignant disease diag-
nosed within the first 6 months after the primary endoscopy. 
An analysis excluding these patients showed that the com-
bined biomarkers still were significantly associated with the 
subsequent risk of developing a primary malignant disease 
(P = 0.0021). 
Discussion
The results of the present study showed that increased levels of 
one or more of four cancer-related soluble protein biomarkers 
at large bowel endoscopy without any findings + no comor-
bidity were associated with a minor, significant risk of subse-
quently developing a primary malignant disease.
The included subjects were referred to endoscopy due to 
symptoms or due to the fact that they were HNPCC fam-
ily members. Therefore, all included subjects were at-risk 
subjects for colorectal neoplasia including malignancies, and 
the frequency of neoplastic findings is relatively high among 
at risk subjects.11 However, most of the symptoms were caused 
by benign findings, for example, diverticula, and more than 
50% of the subjects did not have any bowel pathology at 
all.11 Some of the subjects were referred to endoscopy due to 
Table 1. Distribution of primary cancer among the entire study 
cohort, excluding nonmelanoma skin cancer.
CANCER TYPE ICD-10 NUMBER OF CASES MEAN ET (MONTHS)
C50 8 43
C61 6 38
C18 5 49
C34 5 34
C53 4 20
C25 3 14
C43 3 50
C83 2 80
C72 1 64
C82 1 68
C51 1 43
C22 1 72
C54 1 84
C01 1 59
C56 1 72
Notes: DC50 (malignant neoplasm of breast), DC61 (malignant neoplasm of 
prostate), DC18 (malignant neoplasm of colon), DC34 (malignant neoplasm 
of bronchus and lung), DC53 (malignant neoplasm of cervix uteri), DC25 
(malignant neoplasm of pancreas), DC43 (malignant melanoma), DC83 
(nonfollicular lymphoma), DC72 (malignant neoplasm of spinal cord, 
cranial nerves, and other parts of central nervous system), DC82 (follicular 
lymphoma), DC51 (malignant neoplasm of vulva), DC22 (malignant neoplasm 
of liver and intrahepatic bile ducts), DC54 (malignant neoplasm of corpus 
uteri), DC01 (malignant neoplasm of base of tongue), and DC56 (malignant 
neoplasm of ovary). eT, elapsed time.
Table 2. Distribution of subjects with normal and increased levels of the four specific biomarkers plasma TIMP-1, plasma CEA, plasma CA19-9, 
and serum YkL-40.
BIOMARKER MEDIAN VALUES ng/ml (MIN-MAX) SUBJECTS WITH NORMAL LEVELS SUBJECTS WITH INCREASED LEVELS
TimP-1 75.7 (27.4–175.2) 617 (89%) 74 (11%)
Cea 1.4 (0.5–19.6) 626 (91%) 65 (9%)
Ca19-9 4.7 (2.0–554.4) 615 (89%) 76 (11%)
YkL-40 47.0 (10.0–686.0) 647 (94%) 44 (6%)
Kring et al
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uncharacteristic symptoms that might be caused by a bowel 
lesion, and in most of these cases, the cause of the symptoms 
was never revealed.
Studies with focus on developing blood-based CRC 
screening concepts have shown that soluble biomarkers may 
also be increased among subjects that have no bowel findings 
but various comorbidities;11 even subjects without findings 
and without any comorbidity may have increased levels of sol-
uble protein biomarkers. It has been considered that a rise in 
such biomarker levels may be the first indication of establish-
ment and growth of neoplastic lesions. Although it could not 
be shown for CRC,18 results on elevated levels of C- reactive 
protein appear to identify subjects at risk of developing a 
malignant disease.19,20 Combinations of certain elevated pro-
tein biomarkers may add to the risk profile,14 as confirmed by 
the results of the present study.
Even though the study cohort was limited to 691 sub-
jects, 43 developed primary malignancies, including five with 
CRC. Among these five subjects, two underwent sigmoidos-
copy and developed right-sided colorectal cancer (CC). It is 
considered that the malignant lesions were not missed at that 
time because the diagnoses were established 37 and 84 months 
later, respectively. It cannot be documented, however, whether 
these two subjects had adenoma formation in the right colon 
at the time of sigmoidoscopy.
It is important to note that various primary malignan-
cies that developed in the study period were indeed related to 
increased biomarker levels. Therefore, a couple of questions must 
be answered. First, are the results achieved by chance? The study 
population is limited and, in particular, the age distribution 
of the included subjects is far from similar to the distribution 
among subjects with symptoms of CRC, where the median age 
is 70 years. The number of HNPCC family members reduced 
the median age to 47 and 45 for women and men, respectively, 
where most age-related malignancies do not develop. Therefore, 
subsequent sufficiently sized studies with the correct age distri-
bution may help to clarify that question. It should be considered, 
however, that the median age at diagnosis of primary malignant 
disease in this study was 56 years, with an interquartile range of 
only 50–65 years. This underlines that the developed malignan-
cies were not associated with high age. Second, does elevated 
biomarker levels indicate subsequent examination if endoscopy 
shows no findings? If subsequent research confirms the asso-
ciation between increased biomarker levels in subjects without 
endoscopic findings and subsequent risk of developing malig-
nant diseases, such subjects might be candidates for frequent 
examinations in order to detect primary malignant diseases, 
including extracolonic diseases at an early stage. The number 
of subjects with increased protein biomarker levels in the pres-
ent study is relatively high, with 205 of the 691 subjects hav-
ing increased levels of one or more biomarkers. Based on these 
numbers, specific follow-up to identify early malignant lesions 
cannot be recommended at present. It is important, however, 
to evaluate the present findings in subsequent sufficiently sized 
studies to verify the value of soluble biomarkers in prediction 
of the risk of subsequent malignancy. If confirmed clinically, 
such subjects might be candidates for frequent follow-up. It is 
concluded that increased levels of certain cancer-related soluble 
biomarkers at primary bowel endoscopy without findings and 
without comorbidity may be associated with risk of developing a 
subsequent primary malignant disease. However, the study size 
only allows for raising hypotheses, which should be tested in suf-
ficiently sized studies of subjects at similar age distribution as 
CRC-risk subjects. 
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Figure 1. The figure shows the cumulative incidence of any new cancer 
from the date of primary large bowel endoscopy. The strata are patients 
without elevated soluble biomarker levels (Cea, TimP-1, Ca19-9, and 
YkL-40) (black), patients with one elevated biomarker level (blue) and 
patients with at least two elevated biomarker levels (red).
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